ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0607

Validation Studies of Rheumatoid Arthritis Patient-Reported Outcome Measures in Diverse Populations at Risk for Inequity: A Systematic Review

Cheryl Barnabe1, Aimee Wattiaux2, Jennifer Petkovic3, Dorcas Beaton4, Beverley Shea3, Regina Greer-Smith5, Jennifer Humphreys6, Christie Bartels7, Peter Tugwell3 and Valerie Umaefulam1, 1University of Calgary, Calgary, AB, Canada, 2University of Wisconsin, Madison, WI, 3University of Ottawa, Ottawa, ON, Canada, 4University of Toronto, Toronto, ON, Canada, 5Healthcare Research Associates, Hazel Crest, IL, 6University of Manchester, Manchester, United Kingdom, 7University of Wisconsin School of Medicine and Public Health, Madison, WI

Meeting: ACR Convergence 2021

Keywords: equity, Patient reported outcomes, rheumatoid arthritis, validation

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 7, 2021

Title: Healthcare Disparities in Rheumatology Poster (0594–0622)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Existing patient-reported outcome measures (PROMs) in rheumatoid arthritis (RA) may be limited in their applicability to populations that experience inequities. We conducted a systematic review to identify validation studies for PROMs in populations at risk for inequity.

Methods: A systematic review of MEDLINE and EMBASE was completed. The search strategy was developed to identify measurement property studies for PROMs of interest (selected pain, disease activity, global evaluation and quality of life scales) in patients with RA. We identified experimental, observational, and qualitative studies reporting analysis of feasibility, construct validity and discriminant ability metrics for populations at risk for inequity by various factors including race, ethnicity, culture or language; employment status; gender and sex identity; education level; socioeconomic status; social support; age; health literacy and disability. A narrative synthesis was conducted.

Results: From 19,786 titles and abstracts screened, we identified 14 unique studies reporting validation metrics for pain (n=3), DAS28-ESR or DAS28-CRP (n=2), ACR20 (n=1), patient global assessment (n=2), EQ5D (n=4), and PROMIS® (n=3) by race (n=10 studies), age (n=6 studies), sex and gender identity (n=5 studies), education level (n=2 studies), and disability, literacy, employment status, social support level and socioeconomic status (n=1 study each). Most studies reported construct validity metrics (n=13), with 5 studies reporting on feasibility and 3 studies reporting on discriminant validity metrics. A visual summary of results is presented in the OMERACT Summary of Measurement Properties (SOMP)-Equity Extension table (Table 1). Overall, studies by culture or language demonstrated good measurement property metrics. There was significantly limited assessment of measurement property metrics for other populations at risk for inequity.

Conclusion: Our study highlights important gaps in patient representation in rheumatology research for accepted patient-reported outcome measures. New PROMs being developed for research and clinical practice should ensure and report representation of patients from populations facing inequities in the testing of metrics of feasibility, construct validity and discriminant ability.

OMERACT Summary of Measurement Properties (SOMP)-Equity Extension for Patient-Reported Outcome Measures


Disclosures: C. Barnabe, Pfizer, 1, Gilead, 1, Novartis, 6, Sanofi, 6, Celltrion, 1; A. Wattiaux, None; J. Petkovic, None; D. Beaton, None; B. Shea, None; R. Greer-Smith, None; J. Humphreys, None; C. Bartels, Pfizer, Independent Grants for Learning and Change, 5; P. Tugwell, None; V. Umaefulam, None.

To cite this abstract in AMA style:

Barnabe C, Wattiaux A, Petkovic J, Beaton D, Shea B, Greer-Smith R, Humphreys J, Bartels C, Tugwell P, Umaefulam V. Validation Studies of Rheumatoid Arthritis Patient-Reported Outcome Measures in Diverse Populations at Risk for Inequity: A Systematic Review [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/validation-studies-of-rheumatoid-arthritis-patient-reported-outcome-measures-in-diverse-populations-at-risk-for-inequity-a-systematic-review/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/validation-studies-of-rheumatoid-arthritis-patient-reported-outcome-measures-in-diverse-populations-at-risk-for-inequity-a-systematic-review/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology